How Investors May Respond To Madrigal (MDGL) Adding J&J R&D Leader John C. Reed To Its Board
Madrigal Pharmaceuticals appointed John C. Reed, Johnson & Johnson's Executive Vice President of Innovative Medicine R&D, to its Board of Directors, signaling a strong emphasis on scientific rigor and late-stage development expertise. This addition, while enhancing the company's scientific narrative, doesn't immediately change the investment focus on Rezdiffra's performance and potential payer pushback. Investors are encouraged to examine Madrigal's full financial report and various fair value estimates to form their own investment verdicts.
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding
Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals (NASDAQ:MDGL), automatically sold 664 shares of common stock on August 17, 2026. This sale, priced at $514.97 per share, was executed by the issuer to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Kelley directly retains 11,474 shares of the company's common stock.
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
Shannon Kelley, General Counsel for Madrigal Pharmaceuticals, sold 664 shares of MDGL stock for approximately $341,940 to cover tax obligations related to equity awards. This sale reduced Kelley's stake by 5.47% to 11,474 shares. Despite a 3.9% drop in share price, Madrigal Pharmaceuticals reported better-than-expected quarterly revenue of $364.25 million and an adjusted loss of $1.99 per share, maintaining a "Moderate Buy" consensus rating from analysts.
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes
Madrigal Pharmaceuticals' General Counsel, Kelley T. Shannon, had 664 shares of common stock sold at $514.97 per share on August 17, 2026. This sale was automatically executed by the issuer to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Shannon directly holds 11,474 MDGL common shares.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced the grant of equity inducement awards to 13 new non-executive employees on August 15, 2026. These awards, totaling 4,676 time-based restricted stock units, were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4) to induce employment. The restricted stock units will vest in four equal annual installments, subject to continued employment.
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Madrigal Pharmaceuticals (MDGL) stock appears undervalued based on sales, trading at a P/S ratio of 9.4x compared to an industry average of 11.1x and a fair estimate of 15.0x. Despite a significant 5.4x gain over five years, a recent pullback has prompted a re-evaluation of its attractiveness. While sales valuation looks promising, the key risk lies in the company's ability to convert revenue into durable cash flows, which will justify a higher multiple.
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares
Madrigal Pharmaceuticals (NASDAQ: MDGL) director John C. Reed was granted 647 restricted stock units (RSUs) and options on 1,078 shares. The RSUs will vest 50% on August 15, 2027, and 50% on August 15, 2028, while the stock options, with an exercise price of $507.56 per share, will vest 50% on August 15, 2027, followed by 12.5% quarterly for four periods, all contingent on his continued service. This insider transaction reflects compensation awards, as detailed in a Form 4 SEC filing.
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming
The State of Wyoming recently acquired 2,410 shares of Madrigal Pharmaceuticals (MDGL) worth approximately $1.29 million, with institutions collectively owning 98.5% of the company. Madrigal Pharmaceuticals reported stronger-than-expected quarterly results, and analysts maintain a "Moderate Buy" rating despite recent insider share sales.
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug
Madrigal Pharmaceuticals (MDGL) is attracting retail investor attention due to newly acquired U.S. patents for its lead liver disease drug, Rezdiffra, and ongoing speculation about a potential acquisition, possibly by Eli Lilly. Rezdiffra is Madrigal's sole marketed product, and the company is actively expanding its pipeline through licensing agreements. Despite a 1% dip in share price on Monday, analysts maintain a strong 'Buy' rating for MDGL with a significant upside potential.
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat reduction, and genetically driven disease. Upcoming Phase 3 data could significantly expand Rezdiffra's market to F4 compensated cirrhosis, potentially doubling its U.S. addressable market, though international sales face reimbursement challenges.
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals, Inc. has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson and brings extensive biopharma industry experience from previous executive roles at Sanofi and Roche. His appointment is expected to provide invaluable scientific expertise, strategic leadership, and global R&D insights as Madrigal continues to advance its MASH pipeline following the successful launch of Rezdiffra.
Madrigal Pharmaceuticals, Inc. Announces Appointment of John C. Reed as Board Director
Madrigal Pharmaceuticals, Inc. announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson and has held executive leadership positions at Sanofi and Roche. He is recognized for his significant contributions to biomedical research, including authoring over 900 scientific publications and holding more than 130 patents.
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
Dimensional Fund Advisors LP significantly reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 55.9% in the first quarter, selling 10,801 shares and retaining 8,520 shares valued at approximately $4.46 million. Despite this reduction, institutional investors and hedge funds collectively own 98.5% of the company's stock. Madrigal Pharmaceuticals reported strong quarterly revenues of $364.25 million, a 71.2% year-over-year increase, and an adjusted loss per share that beat analyst expectations, contributing to a "Moderate Buy" consensus rating among analysts.
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals, Inc. announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently an Executive Vice President at Johnson & Johnson, leading research and development for innovative medicine, and has extensive experience in the biopharmaceutical industry. His appointment is expected to strengthen Madrigal's scientific expertise and leadership as it continues to advance its MASH pipeline, including its medication Rezdiffra.
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan
Madrigal Pharmaceuticals, Inc. has appointed Dr. John C. Reed to its Board of Directors, expanding the board from eight to nine members. Dr. Reed, elected as a Class II director, will serve on the Science and Technology Committee. His compensation package includes an annual cash retainer and an initial equity award, detailed in a recent Form 8-K filing.
Madrigal Pharmaceuticals appoints J&J executive to board
Madrigal Pharmaceuticals (NASDAQ:MDGL) has announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, overseeing R&D across various therapeutic areas. Madrigal Pharmaceuticals is focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its FDA and European Commission-approved medication, Rezdiffra.
Form 8K Madrigal Pharmaceuticals Inc For: 12 August By Investing.com
Madrigal Pharmaceuticals Inc. filed a Form 8K on August 12. The article provides the title of the filing and mentions that it was published by Investing.com, along with the stock symbol MDGL and its current performance.
Madrigal's Board Adds Scientist With More Than 900 Papers
Madrigal Pharmaceuticals (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed, currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, brings extensive scientific, leadership, and global drug development experience. His expertise is expected to be invaluable as Madrigal advances its MASH pipeline, including Rezdiffra, and reinforces its commitment to scientific excellence and long-term innovation.
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Royal Bank of Canada
Royal Bank of Canada increased its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 22.5% in the first quarter, bringing its holdings to 12,526 shares valued at approximately $6.6 million. Institutional investors collectively own 98.5% of the company, with other hedge funds also modifying their holdings. Madrigal Pharmaceuticals reported strong quarterly revenue growth of 71.2% year over year and beat analyst estimates for adjusted EPS.
Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones
The article provides a precision trading analysis for Madrigal Pharmaceuticals Inc. (MDGL), highlighting a positive near-term sentiment within a long-term strength context despite a weak mid-term bias. It outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for different risk profiles. The analysis also emphasizes an exceptional 47.1:1 risk-reward setup, targeting a 13.6% gain against a 0.3% risk.
What Is Drawing Fresh Attention To Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals recently reported Q2 results showing increased net losses, drawing attention to its financial performance ahead of an upcoming investor conference. Despite recent volatility, the stock has shown strong long-term momentum with a 1-year total shareholder return of 47.45% and a 5-year return exceeding 5x. The company's valuation narrative suggests it is 24.1% undervalued, primarily due to the potential of its drug Rezdiffra and the expanding market for metabolic and liver diseases.
Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones
This article provides an analysis of Madrigal Pharmaceuticals Inc. (MDGL), highlighting a positive near-term sentiment within a long-term strong context, despite a weak mid-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also details support and resistance levels across near-term, mid-term, and long-term horizons, emphasizing an exceptional risk-reward setup.
What Is Drawing Fresh Attention To Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals (MDGL) is gaining attention after reporting increased net losses in its second-quarter results, ahead of an upcoming investor conference. Despite recent volatility and losses, the stock shows strong long-term momentum with a 1-year total shareholder return of 47.45%. The company's valuation narrative suggests it is 24.1% undervalued, primarily due to the potential of its drug Rezdiffra in the growing MASH market, though future studies and pricing remain key swing factors.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals reported a wider net loss of US$57.94 million in Q2 2026, up from US$42.28 million a year prior, driven by the costs of scaling its MASH-focused business. Despite the increased losses, the company's stock rose 9.1%, indicating investor focus on the long-term potential of its drug Rezdiffra and its broader MASH toolkit, including a recent siRNA partnership. Analysts project significant revenue and earnings growth for Madrigal by 2029, with a fair value indicating a substantial upside from its current price.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals (MDGL) reported a wider Q2 2026 net loss of US$57.94 million, up from US$42.28 million a year prior, largely due to the costs associated with scaling its MASH-focused business. Despite the increased losses, the company's investment narrative still centers on Rezdiffra becoming a standard of care for MASH, with projected revenues of $3.2 billion and earnings of $935.6 million by 2029. Investors are encouraged to consider the implications of these rising expenses on future profitability and the company's valuation.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals reported a wider Q2 2026 net loss of US$57.94 million, up from US$42.28 million a year earlier, reflecting the high costs associated with scaling its MASH-focused business. Despite the increased losses, the stock rose 9.1%. The company's investment narrative hinges on Rezdiffra becoming a standard of care for MASH, with projections of $3.2 billion revenue by 2029.
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion
Madrigal Pharmaceuticals (MDGL) reported a wider net loss of US$57.94 million in Q2 2026, up from US$42.28 million a year earlier, driven by the costs of scaling its MASH-focused business. Despite the increased losses, the article emphasizes that the investment narrative hinges on Rezdiffra becoming a durable standard of care for MASH, with analysts projecting significant revenue and earnings by 2029. The company's efforts to broaden its MASH toolkit beyond Rezdiffra, such as the siRNA partnership, are also noted as potential long-term catalysts.
Bank of America Corp DE Sells 226,498 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Bank of America Corp DE reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 54.4% in the first quarter, selling 226,498 shares and retaining 189,527 shares valued at approximately $99.2 million. Despite this, other institutional investors increased their holdings, and analysts maintain a "Moderate Buy" rating with an average price target of $689.93 against the stock's current price of $510.04. The biopharmaceutical company reported strong quarterly revenue growth of 71.2% year over year and beat analyst expectations for its adjusted loss per share.
Assenagon Asset Management S.A. Buys 108,181 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Assenagon Asset Management S.A. significantly increased its stake in Madrigal Pharmaceuticals, Inc. by 674.7% in the second quarter, purchasing an additional 108,181 shares. This brings their total holding to 124,214 shares, valued at approximately $66.7 million. Despite institutional investors owning 98.5% of the company and a "Moderate Buy" analyst consensus, insiders have recently sold 7,568 shares worth $3.88 million.
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals (Nasdaq: MDGL) announced its participation in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 P.M. EDT. The presentation will be webcast live and a replay will be available. The company focuses on developing therapeutics for MASH, with its medication Rezdiffra being the first approved for MASH with moderate to advanced fibrosis.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to ten new non-executive employees on August 1, 2026, totaling 4,263 time-based restricted stock units. These awards were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4) as an inducement for their employment. The awards vest in four equal installments on the first through fourth anniversaries of the grant date, contingent on continued employment.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals announced it granted equity inducement awards to ten new non-executive employees on August 1, 2026, under its 2025 Inducement Plan. These awards, totaling 4,263 time-based restricted stock units, were approved by the independent Compensation Committee according to Nasdaq Listing Rule 5635(c)(4). The grants serve as an inducement for their employment, with units vesting in four equal installments over four years, subject to continued employment.
Madrigal New Hires Get Stock Awards With Four-Year Vesting
Madrigal Pharmaceuticals (NASDAQ: MDGL) granted equity inducement awards totaling 4,263 time-based restricted stock units to ten new non-executive employees on August 1, 2026. These awards, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments over four years. Vesting is contingent upon the employee's continued employment with the company on each applicable vesting date.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. announced that it granted equity inducement awards to ten new non-executive employees on August 1, 2026, under its 2025 Inducement Plan. These awards, totaling 4,263 time-based restricted stock units, were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) and are intended to be a material inducement for their employment. The restricted stock units will vest in four equal installments over four years, subject to continued employment.
Madrigal’s Aug. 11 Investor Presentation Will Be Webcast Live
Madrigal Pharmaceuticals (Nasdaq: MDGL) announced its participation in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. EDT. The company's presentation will be webcast live and accessible via Madrigal's Investor Relations Events and Presentations page, with a replay available afterward. Madrigal is a biopharmaceutical company focused on treatments for MASH, with its medication Rezdiffra being the first FDA and European Commission approved treatment for the condition.
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals announced its participation in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 P.M. EDT. The company, focused on MASH therapeutics, will webcast its presentation live. Madrigal Pharmaceuticals is known for Rezdiffra, the first FDA and European Commission approved medication for MASH with moderate to advanced fibrosis.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts
Madrigal Pharmaceuticals (NASDAQ:MDGL) has received an average "Moderate Buy" rating from analysts, with 15 out of 18 firms recommending a buy and an average 12-month price target of $689.93, significantly above its current trading price of approximately $514. The company recently surpassed quarterly expectations, reporting a lower-than-anticipated adjusted loss and a substantial 71.2% year-over-year revenue increase. However, the outlook is mixed, as some analysts have revised down longer-term EPS estimates, and company insiders have sold shares totaling about $3.88 million in the last 90 days.
Is Madrigal Pharmaceuticals (MDGL) Undervalued After Wider Losses In Its Second Quarter Results?
Madrigal Pharmaceuticals (MDGL) reported wider net losses in its second quarter, leading to a recent share price drop, though it still shows strong longer-term gains. Despite the wider losses, Simply Wall St's analysis suggests MDGL is undervalued, with a fair value of $678.71, largely due to the potential of its core drug Rezdiffra, which has extended patent protection until 2045. However, the reliance on a single drug and increasing competition pose risks to this optimistic outlook.
Is Madrigal Pharmaceuticals (MDGL) Undervalued After Wider Losses In Its Second Quarter Results?
Madrigal Pharmaceuticals (MDGL) reported wider net losses in its second quarter, leading to a recent stock price decline despite strong longer-term gains. The company's valuation is being reassessed, with a widely followed narrative suggesting it is 31.1% undervalued based on the potential of its core drug, Rezdiffra. However, risks like competition and reimbursement pressure could impact future pricing power.
Barclays lowers Madrigal Pharmaceuticals stock price target to $962
Barclays has lowered its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) stock to $962 from $964, while maintaining an Overweight rating. This decision comes despite recent stock weakness, which the firm views as a strong quarter. Madrigal Pharmaceuticals reported significant Q2 revenue growth, with Rezdiffra sales reaching $364.3 million, a 71% increase year-over-year, although the company experienced a wider net loss and rising expenses.
Madrigal Pharmaceuticals (MDGL) Stock Grapples With Widening Losses Despite Rezdiffra Growth
Madrigal Pharmaceuticals (MDGL) stock dropped 5.2% after reporting widening Q2 losses despite strong Rezdiffra sales and patient growth. The company's Q2 net sales reached US$364.3m, with over 49,000 active U.S. patients on Rezdiffra, but net losses increased to US$57.9m due to heavy investment in the drug and commercial expansion. Investors are questioning the company's path to profitability and whether current liquidity can sustain the rollout amidst rising costs.
Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals reported Q2 2026 results with widened net losses but stronger-than-expected sales of Rezdiffra and new patent protections extending into the 2040s for resmetirom. These developments reinforce the company's investment narrative, suggesting it can maintain its first-in-class position in MASH. While near-term sales momentum is positive, investors should remain aware of rising R&D spending and ongoing net losses.
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals announced strong second-quarter 2026 financial results, with Rezdiffra net sales reaching $364.3 million and over 49,000 patients on the medication, demonstrating significant growth. The company also strengthened its intellectual property with three new patents for resmetirom and initiated a Phase 1 trial for MGL-2086 as part of a combination program for MASH. Madrigal reaffirms its commitment to maximizing Rezdiffra's value and building a leading MASH pipeline, supported by robust clinical data and a new disease awareness campaign.
Earnings call transcript: Madrigal Pharmaceuticals posts strong Q2 2026 sales, shares fall premarket
Madrigal Pharmaceuticals reported strong Q2 2026 net sales of $364.3 million for Rezdiffra, exceeding Wall Street forecasts, yet its shares declined due to a wider net loss and increased expenses. The company highlighted strong commercial execution, with active patients on Rezdiffra surpassing 49,000 and the market for metabolic dysfunction-associated steatohepatitis (MASH) expanding rapidly. Madrigal also provided updates on its robust pipeline and ongoing F4-C outcomes trial, maintaining a positive long-term outlook despite short-term profitability concerns.
Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $364.3M, vs. FactSet Est of $352.1M
Madrigal Pharmaceuticals, Inc. reported its Q2 revenue at $364.3 million, surpassing the FactSet estimate of $352.1 million. The company is focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and has its medication, Rezdiffra, approved for MASH with moderate to advanced fibrosis. Additionally, Madrigal Pharmaceuticals posted a Q2 net loss of $1.99 per share, which was better than FactSet's estimated loss of $2.68 per share.
Madrigal: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Madrigal. Given the limited content, no further details about their financial performance are available.
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong second-quarter 2026 financial results, with Rezdiffra net sales reaching $364.3 million, a 71% year-over-year increase, and over 49,000 patients on the drug. The company also announced the strengthening of Rezdiffra's intellectual property with three new patents and the initiation of a Phase 1 trial for MGL-2086, an oral GLP-1, aiming for combination therapy with Rezdiffra for MASH. Madrigal reaffirmed its commitment to maximizing Rezdiffra's value and building a leading MASH pipeline.
Madrigal Begins Phase 1 Trial of Oral GLP-1 Drug for MASH
Madrigal Pharmaceuticals reported strong second-quarter 2026 net revenues of $364.3 million, a 71% increase year-over-year, driven by high demand for its MASH treatment, Rezdiffra, which now serves over 50,000 active patients. The company also announced
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong second-quarter 2026 financial results, with Rezdiffra net sales reaching $364.3 million and over 49,000 patients on the drug. The company strengthened its intellectual property with three new patents for resmetirom, advanced MGL-2086 (an oral GLP-1) into Phase 1 trials for combination therapy in MASH, and initiated a "MASH Across America" disease awareness campaign. Despite increased operating expenses due to commercial investments and R&D, Madrigal continues to focus on maximizing Rezdiffra's value and building its MASH pipeline.
MDGL Maintained by Canaccord Genuity -- Price Target Raised to $587
Canaccord Genuity has maintained a 'Buy' rating for Madrigal Pharmaceuticals (MDGL) and raised its price target from $578.00 to $587.00. Despite this optimism, the company's GF Score™ of 31/100, high Price-to-Sales ratio, and negative insider activity suggest potential overvaluation and financial challenges, particularly in profitability. Investors are advised to consider these factors while the company focuses on its lead MASH therapeutic, Rezdiffra.
